Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.

Cancer Chemother Pharmacol · 2023 · PMC9905187 · PMID 36625894

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

4 ) shows a slight trend of decreasing frequency of cabozantinib dose modification with higher cabozantinib clearance (lower exposure).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.